Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue from Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Arthritis and Rheumatology

Volumn 68, Issue 1, 2016, Pages 210-217

  Mendoza, Fabian A ^a   Piera Velazquez, Sonsoles ^a   Farber, John L ^a   Feghali Bostwick, Carol ^b   Jiménez, Sergio A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; INTERCELLULAR ADHESION MOLECULE 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; ACTA2 PROTEIN, HUMAN; ACTIN; COL3A1 PROTEIN, HUMAN; COLLAGEN TYPE I, ALPHA 1 CHAIN; CTGF PROTEIN, HUMAN; FN1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SNAI2 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SNAIL; TWIST RELATED PROTEIN 1; TWIST1 PROTEIN, HUMAN;

ADULT; AGED; ARTERIOLE; ARTICLE; CELL ISOLATION; CELL TRANSFORMATION; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL TO MESENCHYMAL PHENOTYPIC TRANSITION; ENDOTHELIUM CELL; FEMALE; GENE; GENE EXPRESSION; GENE PRODUCT; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG PARENCHYMA; MALE; MESENCHYME CELL; MIDDLE AGED; MYOFIBROBLAST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SYSTEMIC SCLEROSIS; WESTERN BLOTTING; COMPLICATION; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; LUNG; LUNG DISEASES, INTERSTITIAL; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTINS; ADULT; AGED; BLOTTING, WESTERN; COLLAGEN TYPE I; COLLAGEN TYPE III; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TWIST-RELATED PROTEIN 1;

EID: 84952064198     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39421     Document Type: Article

References (42)

1. Varga J, Abraham D., Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
2. Gabrielli A, Avvedimento EV, Krieg T., Scleroderma. N Engl J Med 2009; 360: 1989-2003.
3. Matucci-Cerinic M, Kahaleh B, Wigley FM., Systemic sclerosis (scleroderma, SSc) is a vascular disease. Arthritis Rheum 2013; 65: 1953-62.
4. Jimenez SA, Derk CT., Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 37-50.
5. Katsumoto TR, Whitfield ML, Connolly MK., The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011; 6: 509-37.
6. Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE., Pathogenesis of systemic sclerosis. Front Immunol 2015; 6: 272.
7. Beon M, Harley RA, Wessels A, Silver RM, Ludwicka-Bradley A., Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol 2004; 22: 733-42.
8. Gilbane AJ, Denton CP, Holmes AM., Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther 2013; 15: 215.
9. Kendall RT, Feghali-Bostwick CA., Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol 2014; 5: 123.
10. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmouliere A, Varga J, et al., Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012; 180: 1340-55.
11. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G., The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807-16.
12. McAnulty RJ., Fibroblasts and myofibroblasts: their source, function and role in disease. Int J Biochem Cell Biol 2007; 39: 666-71.
13. Falke LL, Gholizadeh S, Goldschmeding R, Kok RJ, Nguyen TQ., Diverse origins of the myofibroblast-implications for kidney fibrosis. Nat Rev Nephrol 2015; 11: 233-44.
14. Poslethwaite AE, Shigemitsu H, Kanagat S., Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004; 16: 733-8.
15. Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B., The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 2009; 86: 1111-8.
16. Herzog EL, Bucala R., Fibrocytes in health and disease. Exp Hematol 2010; 38: 548-56.
17. Lamouille S, Xu J, Derynck R., Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178-96.
18. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, et al., Fate tracing reveals the pericyte and not epithelial origin on myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
19. Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzie PA, et al., Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 2015; 16: 51-66.
20. Zeisberg EM, Taranavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al., Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-61.
21. Goumans MJ, van Zonneveld AJ, ten Dijke P., Transforming growth factor β-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc Med 2008; 18: 293-8.
22. Piera-Velazquez S, Li Z, Jimenez SA., Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 2011; 179: 1074-84.
23. Piera-Velazquez S, Jimenez SA., Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis Tissue Repair 2012; 5 Suppl 1: S7.
24. Arciniegas E, Neves CY, Carrillo LM, Zambrano EA, Ramirez R., Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium 2005; 12: 193-200.
25. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R., Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-7.
26. Li J, Qu X, Bertman JF., Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol 2009; 175: 1380-8.
27. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, et al., Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010; 43: 161-72.
28. LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG, Woda C, et al., Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2012; 19: 1047-53.
29. Rieder F, Kessler SP, West GA, Bhilocha S, de la Motte C, Sadler TM, et al., Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of interstitial fibrosis. Am J Pathol 2011; 179: 2660-73.
30. Yoshimatsu Y, Watabe T., Roles of TGF-β signals in endothelial-mesenchymal transition during cardiac fibrosis. Int J Inflam 2011; 724080.
31. Cooley BC, Nevado J, Mellad J, Yang D, St Hilaire C, Negro A, et al., TGF-β signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci Transl Med 2014; 6: 227ra34.
32. Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Pechoux C, Bogaard HJ, et al., Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 2015; 131: 1006-18.
33. Good RB, Gilbane AJ, Trinder SL, Denton CP, Coghlan G, Abraham DJ, et al., Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension. Am J Pathol 2015; 185: 1850-8.
34. Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, et al., Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58: 2854-65.
35. Marelli-Berg FM, Peek E, Lidington EA, Stauss HJ, Lechler RI., Isolation of endothelial cells from murine tissue. J Immunol Methods 2000; 244: 205-15.
36. Li Z, Jimenez SA., Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum 2011; 63: 2473-83.
37. Nolan T, Hands RE, Bustin SA., Quantification of mRNA using real-time RT-PCR. Nat Protoc 2006; 1: 1559-82.
38. Medici D, Potenta S, Kalluri R., Transforming growth factor-β2 promotes Snail-mediated endothelial mesenchymal transition through convergence of Smad-dependent and Smad-independent signaling. Biochem J 2011; 433: 515-20.
39. Van Meeteren LA, ten Dijke P., Regulation of endothelial cell plasticity by TGF-β. Cell Tissue Res 2012; 347: 177-86.
40. Veraldi KL, Hsu E, Feghali-Bostwick CA., Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease. Curr Rheumatol Rep 2010; 12: 19-25.
41. Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J., Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? [review]. Arthritis Rheumatol 2014; 66: 1967-78.
42. Wells AU, Margaritopoulos GA, Antoniou KM, Denton C., Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med 2014; 35: 213-21.